JAK-STAT saturation limits interferon-induced transcriptional bursting in aged tissues via promoter-proximal pausing

Hypothesis

Aged cells maintain high basal JAK-STAT signaling that occupies STAT dimers on interferon-stimulated gene (ISG) promoters, but the transcriptional machinery stalls after initiation because CDK9‑dependent pause release is depleted. Consequently, ISG mRNA cannot be boosted above the elevated baseline despite intact receptor JAK activity.

Mechanistic basis

Chronic low‑level IFN tone drives continuous STAT3 phosphorylation, leading to persistent promoter binding. In young cells, interferon triggers a burst of CDK9 activity that releases paused RNA polymerase II, producing a sharp rise in ISG transcripts. In aged tissues, prolonged STAT occupancy correlates with reduced CDK9 expression or activity, shifting the equilibrium toward a poised but non‑productive state. This creates a situation where phospho‑STAT levels remain high (signal saturation) yet the dynamic range for transcriptional induction is lost—a form of signaling exhaustion distinct from classic feedback inhibition.

Testable predictions

1. Basal pSTAT3 levels will be higher in aged tendon stem cells and immune cells than in young counterparts, matching published data.
2. Upon acute IFN-gamma or IFN-beta stimulation, the fold‑change in nascent ISG RNA (measured by 4sU‑seq or intron‑specific qPCR) will be significantly blunted in aged cells despite similar or greater increases in pSTAT3 kinetics.
3. CDK9 protein levels or its kinase activity (phospho‑CTD Ser2) will be lower in aged cells after interferon challenge, while total STAT3 binding to ISG promoters (ChIP‑seq) stays elevated.
4. Pharmacological activation of CDK9 (e.g., with a CDK9 agonist) or overexpression of CDK9 will restore the inducible ISG response in aged cells without altering basal pSTAT3.
5. siRNA knock‑down of SOCS1 or SOCS3 will not rescue the inducible defect, indicating the block lies downstream of cytokine receptor feedback.

Experimental design

• Isolate tendon stem cells and peripheral blood monocytes from young (3‑month) and old (24‑month) mice.
• Treat cells with IFN-gamma (10 ng/mL) for 0, 15, 30, 60 min and collect samples for:
  • Western blot of pJAK2, pSTAT3, total STAT3, CDK9, phospho‑RNAPII Ser2.
  • ChIP‑qPCR for STAT3 and CDK9 at ISG promoters (e.g., Irf1, Cxcl10).
  • 4‑sU labeling for 15 min post‑stimulus followed by sequencing to quantify nascent transcription.
• Parallel cultures receive a CDK9 activator (e.g., THZ1 at low dose) or CDK9‑cDNA via lentivirus before IFN challenge.
• Compare fold‑induction of nascent ISG RNA and mature mRNA (RT‑qPCR) between conditions.
• Use statistical interaction tests (age × treatment) to determine whether CDK9 rescue specifically improves inducibility in aged cells.

Potential outcomes and interpretation

If aged cells show unchanged pSTAT3 kinetics but reduced CDK9‑Ser2‑phospho RNAPII and blunted nascent ISG transcription, the hypothesis is supported. Rescue of inducibility by CDK9 activation would demonstrate that the block is transcriptional pause release, not receptor loss or chromatin closure. Failure of CDK9 modulation to affect the response would falsify the model and point toward alternative mechanisms such as promoter‑proximal nucleosome remodeling or STAT co‑factor depletion.

This framework directly tests whether chronic JAK-STAT signaling exhausts the transcriptional burst capacity—a mechanistic distinction that has not yet been addressed in the aging literature.